| ObjectGlioma is currently the most common and most malignant intracranial primary malignant tumor.Its high invasiveness,proliferative and recurrence make patients with poor prognosis,and the average survival time is about 14-16 months,there is an urgent need to seek new molecular therapeutic targets for early diagnosis,targeted therapy and prognosis evaluation.This study mainly explored the expression of biliverdin reductase B（BLVRB）in glioma and the effect of BLVRB expression on the prognosis of glioma patients.Method（1）By retrieving the primary glioma data in the China Glioma Genome Atlas Project（CGGA）,the expression level,expression level and pathological grade of BLVRB in human glioma were analyzed,and the expression level of BLVRB m RNA was explored.Differences in age,pathological grade（WHO grade）,IDH1 mutation type and 1p/19 q co-deletion type.（2）The case information of 102 patients with primary glioma from January 2016 to December 2019 in the No.904 Hospital of the Joint Logistics Support Force was included.All patients were primary intracranial space-occupying and were treated by surgical resection.The results of routine pathological examination were all brain gliomas of different grades.In this study,immunohistochemical staining data combined with postoperative follow-up results of patients,and statistical methods were used to evaluate the relationship between the expression level of BLVRB in glioma tissue and the pathological grade.The follow-up data of 102 patients with primary gliomas selected in this study had the informed consent of their families and the consent of the hospital ethics committee.Immunohistochemical staining results were independently judged and confirmed by two pathologists.（3）Univariate analysis,Cox regression and Kaplan-Meier method were used to evaluate and analyze the relationship between the expression level of BLVRB and the prognosis of primary glioma patients by SPSS20 statistical software.（4）By searching the biological functions and possible biological pathways of BLVRB in the NCBI database（National Center for Biotechnology Information）and THPA database（The Human Protein Atlas）,the functional analysis of BLVRB was performed through GO enrichment analysis and Pathway annotation,including the possible biological roles in the normal physiological activities of the human body,related mechanisms and pathways,and possible roles in diseases and tumors.ResultThrough the in-depth analysis of BLVRB data in the CGGA database and the results of immunohistochemistry,it was shown that with the gradual increase of the pathological grade of the patient’s glioma,the expression levels of BLVRB m RNA and BLVRB in the tissue were also higher（P<0.05）.Through statistical univariate analysis,the expression level of BLVRB m RNA in age ≥42 years old,IDH1 wild type,1p/19 q non-codeletion glioma,the expression level in tumor group was significantly higher than that in control group,the difference was statistically significant Significance（P<0.05）.Cox analysis showed that the expression level of BLVRB in glioma tissue was an independent risk factor for the prognosis of glioma patients,and the high expression of BLVRB in glioma tissue of patients indicated that the overall survival period was shorter than that of the low expression group compared with the overall（P<0.05）.Through GO functional enrichment analysis and pathway annotation,it was found that BLVRB is involved in biological processes such as heme catabolism and redox in human physiological metabolic activities.ConclusionThere is abnormal expression of BLVRB in brain glioma,and its expression level is related to the pathological grade of glioma.With the increase of glioma grade,the expression of BLVRB gradually increases,and the high expression of BLVRB indicates poor prognosis in glioma patients and is an independent risk factor for predicting the prognosis of glioma patients.BLVRB has the potential to be an emerging marker and potential therapeutic target for predicting the prognosis of glioma patients. |
PDF Full Text Request